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Introduction
The tumor suppressor p53 plays a pivotal role in many 
physiological processes, including metabolism and main-
tenance of genomic stability. In order to allow normal 
cell proliferation and to maintain cell viability during 
absence of stress signals, the activity of p53 is kept 
under strict control, predominantly by the protein 
product of the murine double minute 2 gene, MDM2, 
and its homolog MDM4, acting in concert [1]. It is 
well established that MDM2 and p53 are linked in an 
autoregulatory negative feedback loop, where p53 tran-
scriptionally induces MDM2 and MDM2 downregulates 
p53 [2], mainly by direct inhibition and/or proteolytic 
degradation [3–5]. Although MDM4 alone is unable 
to target p53 for ubiquitin- proteasome- dependent deg-
radation [6], the MDM2/MDM4 heterodimer has been 
shown more potent degrading the p53 protein as com-
pared to the MDM2 homodimer [7, 8]. Additionally, 
using Mdm2/Mdm4/p53 triple knockout MEFs, Yuan 
and colleagues showed that an Mdm2/Mdm4 heter-
odimer is required for the E3 ligase activity of Mdm2 
[9]. These data suggest that elevated levels of MDM4 
may contribute to reduced p53 activity and tumor 
development. In line with this, the MDM4 gene has 
been found amplified in malignant gliomas with no 
TP53 mutations or MDM2 amplifications [10, 11] as 
well as in breast cancer [12], and acute lymphoblastic 
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Abstract
The MDM4 protein plays an important part in the negative regulation of the 
tumor suppressor p53 through its interaction with MDM2. In line with this, 
MDM4 amplification has been observed in several tumor forms. A polymorphism 
(rs4245739 A>C; SNP34091) in the MDM4 3′ untranslated region has been 
reported to create a target site for hsa- miR- 191, resulting in decreased MDM4 
mRNA levels. In this population- based case–control study, we examined the 
potential association between MDM4 SNP34091, alone and in combination with 
the MDM2 SNP309T>G (rs2279744), and the risk of breast- , colon- , lung- , and 
prostate cancer in Norway. SNP34091 was genotyped in 7,079 cancer patients 
as well as in 3,747 gender- and age- matched healthy controls. MDM4 SNP34091C 
was not associated with risk for any of the tumor forms examined, except for 
a marginally significant association with reduced risk for breast cancer in a 
recessive model (OR = 0.77: 95% CI = 0.59–0.99). Stratifying according to 
MDM2 SNP309 status, we observed a reduced risk for breast cancer related to 
MDM4 SNP34091CC among individuals harboring the MDM2 SNP309GG geno-
type (OR = 0.41; 95% CI = 0.21–0.82). We conclude, MDM4 SNP34091 status 
to be associated with reduced risk of breast cancer, in particular in individuals 
carrying the MDM2 SNP309GG genotype, but not to be associated with either 
lung- , colon- or prostate cancer.
Cancer Medicine
Open Access
1902 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
L. B. Gansmo et al.MDM4 SNP34091 and cancer risk
leukemia [13]. Furthermore, studies in transgenic mice 
show that overexpression of Mdm4 induced spontane-
ous tumor formation and accelerated tumorigenesis 
[14].
Single- nucleotide polymorphisms (SNP) affecting the 
levels of both MDM2 and MDM4 have been reported 
[15–18]. While MDM2 SNP309T>G (rs2279744) and 
SNP285G>C (rs117039649) both affect MDM2 transcrip-
tion, MDM4 SNP34091A>C (rs4245739) has been found 
to affect MDM4 mRNA stability and protein levels [17, 
18]. SNP34091 is located in the 3′ untranslated region 
of MDM4, and was found to create a functional target 
site for hsa- miR- 191 and hsa- miR- 887. Both miRs bind 
to the MDM4 SNP34091 C- allele with higher affinity 
than to the MDM4 SNP34091 A- allele, leading to miR-
mediated decrease in MDM4 protein levels in cells car-
rying the MDM4 SNP34091C variant [17, 18]. Genotype 
AA was recorded to be more frequent in  patients 
with high-grade than low- grade ovarian carcinoma [18]. 
Furthermore, previous studies have indicated the 
SNP34091C allele to be associated with a reduced risk 
for non- Hodgkin lymphoma [19], breast cancer [20], 
esophageal squamous cell carcinoma [21], and prostate 
cancer [22].
Contrasting these results, genome wide association stud-
ies (GWAS) reported the C allele to be associated with 
an increased risk for estrogen receptor negative, and in 
particular, triple negative breast cancer [23–25].
In this study, we assessed the impact of MDM4 SNP34091 
status on the risk of cancer of the breast, lung, prostate, 
and colon in a large population- based cohort of Caucasian 
descent.
Materials and Methods
Study population
From the population- based Cohort of Norway (CONOR) 
study [26], we genotyped 7079 incident cancer cases and 
3747 healthy controls, described in detail previously [27]. 
Thus, we examined the potential effect of MDM4 
SNP34091A>C by analyzing the four major cancer forms; 
breast (n = 1,717), lung (n = 1,331), colon (n = 1,531), 
and prostate (n = 2,500). On the basis of previously pub-
lished allele frequencies in healthy controls and breast cancer 
cases [23], we found our study design to provide adequate 
statistical power (β- values ranging from 0.83 to 0.95 for 
the four cancer sample sets, given an α- value of 0.05).
MDM4 SNP34091 genotyping
All samples were genotyped for MDM4 SNP34091 status 
using a custom LightSNiP assay (TIB MOLBIOL 
Syntheselabor GmbH, Berlin, Germany) on a LightCycler 
480 II instrument (Roche, Basel, Switzerland). The  reactions 
were performed in a final reaction volume of 10 μL, con-
taining 1 μL LightCycler®FastStart DNA Master HybProbe 
mix (Roche Diagnostics), 0.5 μL LightSNiP mix (TIB 
MOLBIOL), 3 mmol/L MgCl2 and 10–50 ng DNA. The 
thermocycling and melting curve conditions were as follows: 
10 min initial denaturation/activation at 95°C, followed by 
45 cycles of denaturation at 95°C for 10 sec, annealing for 
10 sec at 60°C and elongation at 72°C for 15 sec. Subsequent 
to the thermocycling amplification the high- resolution melt-
ing (HRM) step was initiated with a denaturation step at 
Table 1. MDM4 SNP34091 distribution and cancer risk.
Cases/controls
Genotype OR (95% CI)
P- value
OR (95% CI)
P- value
SNP34091 n (%) SNP34091 SNP34091
AA AC CC CC versus AA+AC CC+AC versus AA
Controls 2042 (54.5) 1439 (38.4) 266 (7.1) 1.00 – 1.00 –
 Women 1021 (54.6) 703 (37.6) 146 (7.8) 1.00 – 1.00 –
 Men 1021 (54.4) 736 (39.2) 120 (6.4) 1.00 – 1.00 –
Colon cancer1 823 (53.8) 600 (39.2) 108 (7.1) 1.04 (0.82–1.32) 0.737 1.04 (0.93–1.18) 0.484
 Women2 429 (55.1) 293 (37.7) 56 (7.2) 1.02 (0.73–1.41) 0.919 1.01 (0.85–1.20) 0.941
 Men3 394 (52.3) 307 (40.8) 52 (6.9) 1.09 (0.78–1.54) 0.601 1.10 (0.92–1.30) 0.295
Lung cancer1 715 (53.7) 515 (38.7) 101 (7.6) 1.11 (0.87–1.41) 0.396 1.03 (0.91–1.17) 0.662
 Women2 264 (53.1) 194 (39.0) 39 (7.9) 1.05 (0.73–1.53) 0.781 1.07 (0.87–1.30) 0.535
 Men3 451 (54.1) 321 (38.5) 62 (7.4) 1.19 (0.86–1.64) 0.288 1.01 (0.86–1.19) 0.912
Prostate cancer3 1412 (56.5) 927 (37.1) 161 (6.4) 1.01 (0.79–1.29) 0.946 0.92 (0.82–1.04) 0.182
Breast cancer2 966 (56.3) 643 (37.5) 108 (6.3) 0.77 (0.59–0.99) 0.045 0.93 (0.82–1.07) 0.317
1Sex and age adjusted (logistic regression).
2Calculations with female controls only, age adjusted.
3Calculations with male controls only, age adjusted.
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95°C for 30 sec, followed by melting from 40°C to 75°C 
with a ramp rate of 0.19°C/sec and finally a cooling step 
at 40°C for 30 sec. The HRM curve profiles were analyzed 
by the Melt Curve Genotyping software (version 1.5) on 
the LightCycler® 480 II instrument (Roche Diagnostics).
Statistical analysis
Potential deviations from Hardy–Weinberg equilibrium 
were assessed by calculating the expected genotype dis-
tribution based on the observed allele frequencies and 
comparing the output with the observed genotype distri-
bution using Chi- square tests.
Potential associations between MDM4 SNP34091 and 
the risk of any of the cancer types tested as well as cancer 
risk within different subgroups were estimated by 
calculating Odds Ratios (OR) with 95% confidence in-
tervals (CI) and logistic regression adjusting for sex and 
age. In addition, for colon- and lung cancer, overall cal-
culations were performed including both genders using 
the Mantel–Haenszel test (sex adjusted).
All statistical analyses were performed using the IBM 
SPSS 22 software package (IBM Corp, Armonk, NY, USA) 
and Stata 13.0 for Windows (Stata Corp, College Station, 
TX, USA). All P- values are given as two- sided.
Results
Distribution of MDM4 SNP34091
In this study, 7,079 cancer cases and 3,747 healthy controls 
were analyzed for MDM4 SNP34091 status. Among the 
Figure 1. Impact of MDM4 SNP34091 on cancer risk. Forest plots showing the effect of SNP34091 on cancer of the colon, lung, prostate, and breast, 
as compared to healthy controls, among the total study population (A) and among individuals harboring the MDM2 SNP309GG genotype (B).
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healthy individuals, the percentages harboring the three 
different genotypes (MDM4 SNP34091AA, AC, and CC) 
were recorded to be 54.5%, 38.4%, and 7.1%, respectively. 
The genotype frequencies were found to be in Hardy–
Weinberg equilibrium (P > 0.9). A comprehensive overview 
of the MDM4 SNP34091 distribution in the healthy con-
trols as well as the four cancer types analyzed is given 
in Table 1. Among the healthy controls, no substantial 
gender difference with respect to genotype distribution 
was observed (P = 0.193).
MDM4 SNP34091 status and cancer risk in 
four major cancer forms
In order to assess the potential impact of MDM4 SNP34091 
status on cancer risk, we compared the frequency of the 
MDM4 SNP34091 genotypes among breast- (n = 1,717), 
lung- (n = 1,331), colon- (n = 1,531), and prostate cancer 
(n = 2,500) patients to healthy controls (n = 3,747). We 
observed no significant correlation between MDM4 SNP34091 
status and the risk of either cancer in the colon, lung, or 
prostate, either in a dominant or a recessive model (SNP34091 
CC+AC vs. AA, or CC vs. AA+AC, respectively). Furthermore, 
analyzing tumors of the right or the left side of the colon 
separately, revealed no significant effect of MDM4 SNP34091 
status and cancer risk in either of the two groups (Table 
S1). We observed, however, a marginally significant associa-
tion with reduced risk for breast cancer among individuals 
harboring the SNP34091CC genotype (recessive model; 
OR = 0.77; 95% CI = 0.59–0.99; Table 1, Fig. 1A).
Since 92.6% of the lung cancer patients (from whom 
we had data) were smokers, excluding nonsmokers from 
the analysis had no impact on the estimates (Table S2).
Potential interactions between MDM4 
SNP34091 status and MDM2 promoter SNPs
Previously, we assessed SNP status of the MDM4 partner 
MDM2 across the same population of cancer patients 
and healthy controls [27]. While the MDM2 SNP309GG 
genotype has been associated with a nonsignificantly 
 increased risk for breast cancer, breast cancer patients 
carrying the SNP309GG genotype have been found par-
ticularly sensitive to cancer risk reduction by a second 
MDM2 SNP (SNP285G>C) [27]. This observation has 
also been recorded in another separate sample set of 
breast cancer patients [16].
Since MDM4 forms a heterodimer with MDM2 and 
promotes MDM2- mediated polyubiquitination and subse-
quent degradation of p53, we investigated potential inter-
actions/synergistic effects between MDM4 SNP34091 and 
MDM2 SNPs with respect to cancer risk. Stratifying ac-
cording to MDM2 SNP309 status (SNP309TT, SNP309TG, 
and SNP309GG) we found the MDM4 SNP34091CC geno-
type (recessive model) to be significantly associated with 
reduced risk of breast cancer among patients carrying the 
SNP309GG genotype (OR = 0.41; 95% CI = 0.21–0.82; 
Table 2, Fig. 1B). Notably, when refining the OR estimates 
by removing individuals harboring the less frequent MDM2 
SNP285C allele, which antagonizes SNP309G- induced tran-
scriptional enhancement [16], this negative association 
became slightly stronger (gender adjusted OR = 0.40; 95% 
CI = 0.19–0.85; Table S3).
In addition to assessing the effect of MDM4 SNP34091 
within subgroups of MDM2 SNP309 genotypes, we also 
explored differences between all possible combinations of 
MDM4 SNP34091/MDM2 SNP309 genotypes. By doing so, 
Table 2. MDM4 SNP34091 among MDM2 SNP309GG.
Cases/controls
Genotype OR (95% CI)
P- value
OR (95% CI)
P- value
SNP34091 n (%) SNP34091 SNP34091
AA AC CC CC versus AA+AC CC+AC versus AA
Controls 294 (58.6) 167 (33.3) 41 (8.2) 1.00 – 1.00 –
 Women 149 (58.7) 77 (30.3) 28 (11.0) 1.00 – 1.00 –
 Men 145 (58.5) 90 (36.3) 13 (5.2) 1.00 – 1.00 –
Colon cancer1 111 (59.7) 60 (32.3) 15 (8.1) 1.02 (0.54–1.93) 0.947 0.98 (0.69–1.39) 0.903
 Women2 56 (59.6) 30 (31.9) 8 (8.5) 0.82 (0.33–1.99) 0.653 1.09 (0.65–1.83) 0.745
 Men3 55 (59.8) 30 (32.6) 7 (7.6) 1.60 (0.59–4.34) 0.356 1.03 (0.63–1.70) 0.898
Lung cancer1 100 (54.6) 73 (39.9) 10 (5.5) 0.73 (0.35–1.54) 0.413 1.18 (0.83–1.68) 0.357
 Women2 38 (57.6) 25 (37.9) 3 (4.6) 0.43 (0.12–1.52) 0.190 1.17 (0.66–2.10) 0.588
 Men3 62 (53.0) 48 (41.0) 7 (6.0) 1.13 (0.43–3.00) 0.799 1.30 (0.82–2.05) 0.264
Prostate cancer3 184 (53.5) 143 (41.6) 17 (4.9) 0.99 (0.46–2.11) 0.974 1.26 (0.90–1.77) 0.176
Breast cancer2 160 (63.8) 77 (30.7) 14 (5.6) 0.41 (0.21–0.82) 0.012 0.75 (0.52–1.10) 0.139
1Sex and age adjusted (logistic regression).
2Calculations with female controls only, age adjusted.
3Calculations with male controls only, age adjusted.
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we confirmed the MDM4 SNP34091CC/MDM2 SNP309 
GG genotype to associated with reduced risk of breast 
cancer (OR = 0.47; 95% CI = 0.24–0.92, when compared 
with the highest risk genotype (MDM4 SNP34091AA/MDM2 
SNP309GG), data not shown).
No effect on the risk of any of the other cancer forms 
with respect to MDM4 SNP34091 status within the differ-
ent MDM2 genotypes, either when stratifying cancer of 
the colon according to tumors of the right or left side, or 
when excluding the nonsmokers in lung cancer, was 
recorded.
Discussion
In this study, we observed no association between MDM4 
SNP34091 status and the risk for colon- , prostate- , or 
lung cancer, while a marginally significant association with 
reduced risk of breast cancer was observed. Our observa-
tion in breast cancer is similar to, but weaker than the 
observations of Liu and colleagues, who found the 
SNP34091 AC and CC genotypes to be significantly 
 associated with reduced breast cancer risk compared with 
the AA genotype in two different Chinese populations 
[20]. In contrast, GWAS have found an elevated OR for 
ER negative breast cancer related to the SNP34091C allele 
in Caucasians but not among Asians [23–25]. Regrettably, 
information on receptor status was not available for the 
breast cancer patients examined in this study; thus, a 
potential effect of SNP43091 status in the minor group 
of patients harboring ER negative tumors may have been 
overlooked. Regarding prostate cancer risk, we observed 
a weak, non- significant association between MDM4 
SNP34091C and reduced risk in the dominant model. 
This is in line with data from the majority of individual 
datasets from European populations, included in a recent 
large GWAS [22], and mirrors our previous findings re-
lated to MDM2 polymorphisms [27–29].
This study is, to our knowledge, the first population- based 
case–control study assessing the impact of MDM4 SNP34091 
on cancer risk in lung- and colon cancer. Previous case–
control studies assessing this variant in other cancer forms 
(esophageal squamous cell carcinoma and non- Hodgkin 
lymphoma), including breast cancer, have found the 
SNP34091C allele to be associated with reduced risk, but 
have all been performed in Chinese populations [19–21].
Regarding the variations in the results between studies 
of different ethnic groups, notably, there is a large dif-
ference in the distribution of MDM4 SNP34091 between 
Europeans and Asians with a MAF of 0.26 and 0.05, 
respectively [30], possibly affecting the power of studies 
in Asian populations even though the numbers of patients 
included are large. Also, a possible explanation for the 
discrepancy may be yet unknown functional SNP(s) that 
are in linkage disequilibrium (LD) with SNP34091: There 
are examples of functional SNPs in LD where the SNPs 
have different geographical distributions and thus confer 
diverging risk estimates between Europeans and Asians, 
for example, the two MDM2 SNPs; SNP309 and SNP285 
[30–33]. On the other hand, the possibility of publication 
bias, where case–control studies reporting positive results 
are favored cannot be excluded.
After stratifying according to MDM2 SNP309 status, 
we found a reduced risk for breast cancer among indi-
viduals harboring the MDM4 SNP34091CC/MDM2 
SNP309GG genotype, and this association was stronger 
after removing individuals harboring the MDM2 SNP285C 
allele, previously shown to antagonize SNP309G- induced 
transcription elevation [16]. Interestingly, the MDM4 
SNP34091C allele, similar to SNP285G>C seems to execute 
their effects on breast cancer risk among individuals car-
rying the SNP309GG genotype only [16, 27].
In conclusion, we found no association between the MDM4 
SNP34091 status and risk for lung- , prostate- , or colon 
cancer, and a weak association with breast cancer, applying 
the candidate gene approach. The latter finding was sub-
stantiated by the observation of a seemingly synergistic effect 
between the MDM2 SNP309GG and MDM4 SNP34091AA 
genotypes on increased risk for breast cancer.
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